Blasts More Than 20 Percent of Peripheral Blood White Cells
1 clinical trials · Condition
◉ Watch Blasts More Than 20 Percent of Peripheral Blood White Cells
| Record | Firm | Date |
|---|---|---|
| Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia (NCT02257138) | M.D. Anderson Cancer Center | 2015-02-12 |
Track Blasts More Than 20 Percent of Peripheral Blood White Cells automatically
Every clearance here is in the API, with alerts when new ones post.